Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age from 18 to 70~* Patient suffering migraine or probable migraine (diagnosis made by neurologist according to IHCD3)~* Present migraine attack lasting ≤ 72 hours~* Headache intensity moderate or severe on the verbal ordinal scale (4 levels: no headache, mild, moderate or severe)~* Patient requiring parenteral treatment~* Affiliation to the French Health-care System sécurité sociale~Exclusion Criteria:~* abnormalities of neurological exam, seizure, fever (≥ 38°C), and/or SBP≥180 and/or DBP≥110 mmHg~* suspicion of secondary headache~* inability to understand the consent or scales~* pregnancy or breast-feeding~* known respiratory or liver insufficiency~* acute alcohol consumption or alcoholism~* myasthenia~* Patient requiering treatment with sumatriptan SC, particularly in the event of failure of an anti-inflammatory drug at an effective dose taken within 6 hours~* recent use of benzodiazepines (\< 24h diazepam, clonazepam, clorazepate ; \< 6h alprazolam, lorazepam, midazolam)~* recent use of pain killers (\< 2h)~* contraindication to any of the investigational medication~* contraindication to intravenous access~* previous participation to this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Control arm (Type: PLACEBO_COMPARATOR): placebo and standard care :~* Placebo IV~* Ketoprofen 100 mg IV (if nausea-vomiting)~* Metoclopramide 10 mg IV(if nausea-vomiting)
- Experimental arm (Type: EXPERIMENTAL): clorazepate and standard care :~* Clorazepate 20 mg IV~* Ketoprofen 100 mg IV (if nausea-vomiting)~* Metoclopramide 10 mg IV(if nausea-vomiting)

Based on this trial design, predict the completion outcome and termination type (if applicable).